BioSpace News Archive

There have been some concerns over the accuracy of COVID-19 rapid antigen tests—the clinical diagnostic tests that evaluate for active infections by testing for the presence of the virus’s antigens.

Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.

“As true leaders in our field, both companies came to an agreement which benefits our customers and brings clarity to the industry. ''It shows our common goal to make high quality iPSC therapies available at affordable cost to our customers. Additionally, we are pleased to expand the license-use of our innovative Nucleofector™ technology granted to FUJIFILM Cellular Dynamics

Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic metabolic diseases, released today a poster presentation on the therapeutic findings of its Gel-B (GS300) at The Liver Meeting, the American Association for the Study of Liver Disease’s (AASLD) annual conference.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Tim Walbert, chairman, president and chief executive officer, has been honored with the 2020 RARE Champion of Hope Industry Partner award by Global Genes, a nonprofit organization that connects, empowers and inspires the rare disease community.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of its abstract featuring data from one of the pivotal Phase 3 studies (PROTECT) evaluating Sci-B-Vac®, the company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, in an e-poster presentation at the American Association for the Study of Liver Diseases (AASLD

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced new analyses from its maralixibat and volixibat clinical programs, as featured at the Annual Meeting of the American Association for the Study of Liver Diseases – The Liver Meeting Digital Experience

OtoNexus Medical Technologies has been selected as a finalist for Red Herring’s Top 100 North America award, one of the technology industry’s most prestigious prizes.

Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “On the Trail of Better Therapeutics for Depression.

Greenwich Biosciences, U.S. subsidiary of GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, will present data from an analysis of three Phase 3 clinical trials of nabiximols in spasticity among persons with multiple sclerosis (MS) at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Virtual Annual Assembly